Dorzolamide with timolol

PBAC's latest decision on Dorzolamide with timolol: Recommended (2022). Considered for Treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma when concomitant therapy is appropriate.

Eligible population

Patients with elevated intraocular pressure due to ocular hypertension or open-angle glaucoma whose condition is inadequately controlled with monotherapy.

Therapy area

Ophthalmology

Line of therapy

Any

Evidence base

Cost-minimisation

Primary endpoint

Cost-minimisation

Comparator

Cosopt

Economic model

Cost-minimisation

ICER note

This is a Committee Secretariat submission for a bioequivalent formulation (preservative-free multi-dose bottle). No economic evaluation was conducted; the submission estimated no financial implications to PBS/RPBS.

Similar precedents

• Brinzolamide/brimonidine tartrate
  similarity 0.79
• Bimatoprost
  similarity 0.78
• Betaxolol, bimatoprost, bimatoprost + timolol, brimonidine, brimonidine + timolol, brinzolamide, brinzolamide + timolol, dorzolamide, dorzolamide + timolol, latanoprost, latanoprost + timolol, pilocarpine, timolol, travoprost, timolol + travoprost
  similarity 0.78
• Latanoprost with timolol maleate
  similarity 0.75
• Aflibercept
  similarity 0.63
• Aciclovir
  similarity 0.62